Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 74

Related Articles by Review for PubMed (Select 16219936)

1.

Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.

Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, Isaacs C, Olopade OI, Neuhausen SL, van 't Veer L, Eeles R, Evans DG, Tomlinson G, Matloff E, Narod SA, Eisen A, Domchek S, Armstrong K, Weber BL; PROSE Study Group.

J Clin Oncol. 2005 Nov 1;23(31):7804-10. Epub 2005 Oct 11.

2.

Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.

Rebbeck TR.

J Clin Oncol. 2000 Nov 1;18(21 Suppl):100S-3S. Review.

PMID:
11060335
3.

Bilateral risk-reducing oophorectomy in BRCA1 and BRCA2 mutation carriers.

Domchek SM, Stopfer JE, Rebbeck TR.

J Natl Compr Canc Netw. 2006 Feb;4(2):177-82. Review.

PMID:
16451773
4.

Prophylactic oophorectomy in women at increased cancer risk.

Domchek SM, Rebbeck TR.

Curr Opin Obstet Gynecol. 2007 Feb;19(1):27-30. Review.

PMID:
17218848
5.

Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature.

Calderon-Margalit R, Paltiel O.

Int J Cancer. 2004 Nov 10;112(3):357-64. Review.

PMID:
15382059
6.

Hormonal prevention of hereditary breast cancer.

Narod SA.

Ann N Y Acad Sci. 2001 Dec;952:36-43. Review.

PMID:
11795442
7.

Breast cancer and ovarian cancer genetics.

Edlich RF, Winters KL, Lin KY.

J Long Term Eff Med Implants. 2005;15(5):533-45. Review.

PMID:
16218901
8.

Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy.

Gadducci A, Biglia N, Cosio S, Sismondi P, Genazzani AR.

Gynecol Endocrinol. 2010 Aug;26(8):568-77. doi: 10.3109/09513590.2010.487609. Review.

PMID:
20632911
9.

Efficacy of risk-reducing salpingo-oophorectomy in women with BRCA-1 and BRCA-2 mutations.

Olopade OI, Artioli G.

Breast J. 2004 Jan-Feb;10 Suppl 1:S5-9. Review.

PMID:
14984481
10.

Radiotherapy for breast cancer in BRCA1/BRCA2 carriers: clinical issues and management dilemmas.

Pierce L.

Semin Radiat Oncol. 2002 Oct;12(4):352-61. Review.

PMID:
12382193
11.

Inherited predisposition and breast cancer: modifiers of BRCA1/2-associated breast cancer risk.

Rebbeck TR.

Environ Mol Mutagen. 2002;39(2-3):228-34. Review.

PMID:
11921193
12.

[Genetic test and prophylactic treatment in breast cancer families].

Miyoshi Y, Noguchi S.

Gan To Kagaku Ryoho. 2002 Apr;29(4):512-22. Review. Japanese.

PMID:
11977534
13.

Screening and follow-up of the patient at high risk for breast cancer.

Willey SC, Cocilovo C.

Obstet Gynecol. 2007 Dec;110(6):1404-16. Review.

PMID:
18055740
14.

[Hereditary breast and ovarian cancer: primary and secondary prevention for BRCA1 and BRCA2 mutation carriers].

Llort G, Peris M, Blanco I.

Med Clin (Barc). 2007 Mar 31;128(12):468-76. Review. Spanish.

PMID:
17408542
15.

Management updates for women with a BRCA1 or BRCA2 mutation.

Nusbaum R, Isaacs C.

Mol Diagn Ther. 2007;11(3):133-44. Review.

PMID:
17570734
16.

Hereditary ovarian cancer--assessing risk and prevention strategies.

Pavelka JC, Li AJ, Karlan BY.

Obstet Gynecol Clin North Am. 2007 Dec;34(4):651-65, vii-viii. Review.

PMID:
18061862
17.

Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.

Kauff ND, Barakat RR.

J Clin Oncol. 2007 Jul 10;25(20):2921-7. Review.

PMID:
17617523
18.

Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature.

Liede A, Karlan BY, Narod SA.

J Clin Oncol. 2004 Feb 15;22(4):735-42. Review.

PMID:
14966099
19.

A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer.

Michelsen TM, Dørum A, Dahl AA.

Gynecol Oncol. 2009 Apr;113(1):128-33. doi: 10.1016/j.ygyno.2008.12.024. Epub 2009 Jan 29. Review.

PMID:
19178933
20.

The role of estrogens in BRCA1/2 mutation carriers: reflections on the past, issues for the future.

de Carvalho M, Jenkins J, Nehrebecky M, Lahl L.

Cancer Nurs. 2003 Dec;26(6):421-30. Review.

PMID:
15022973
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk